Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Failure With Preserved Ejection Fraction (HFpEF) Clear all
Active, not recruiting Not applicable Interventional

RESPONDER-HF Trial

NCT05425459
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic
Interventions
Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Device · Other
Lead sponsor
Corvia Medical
Industry
Eligibility
40 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
33
States / cities
Phoenix, Arizona • La Jolla, California • Long Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

NCT03877224
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 150 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Phase 2 Interventional

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06616974
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose A, TX000045- Dose B, Placebo
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Terminated No phase listed Observational

HFpEF and Symptomatic Obstructive Iliofemoral Venous Disease Study

NCT04964817
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Venous Disease
Interventions
Not listed
Lead sponsor
Prairie Education and Research Cooperative
Industry
Eligibility
40 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Phase 2 Interventional

Metformin for Pulmonary Hypertension HFpEF

NCT03629340
View directory record Official record
Conditions
Pulmonary Hypertension, Heart Failure
Interventions
Metformin, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Not applicable Interventional

Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction

NCT04546555
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Dual chamber pacemaker, Accelerated Physiologic Pacing, Nocturnal Pacing
Device · Other
Lead sponsor
Daniel L Lustgarten
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jun 11, 2026, 3:42 PM EDT
Not listed Phase 1 Interventional

Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor

NCT05745337
View directory record Official record
Conditions
Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jun 11, 2026, 3:42 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

NCT03043651
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Not applicable Interventional

The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)

NCT06702501
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
PeriCut Catheter System performs minimally invasive pericardiotomy
Device
Lead sponsor
Heart Failure Solutions, Inc.
Industry
Eligibility
30 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Early Phase 1 Interventional

Transthyretin Cardiac Amyloidosis in HFpEF

NCT03414632
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
99mTc-PYP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions
liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

NCT03057951
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,988 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
135
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Not applicable Interventional

MOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection Fraction

NCT06670001
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Gamification plus social incentive, Gamification plus competition
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Tailored Exercise Training Study Among Adults With HFpEF

NCT07223242
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Interventions
Moderate-intensity continuous training (MCT), Resistance training, Weight loss
Behavioral · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

NCT02772068
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Istaroxime, Exercise
Drug · Other
Lead sponsor
Benjamin Levine
Other
Eligibility
60 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Jun 11, 2026, 3:42 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT06763549
View directory record Official record
Conditions
Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncopation, Syncope, Ischemic Cardiovascular Disease, STEMI, STEMI (ST Elevation MI), Atrial Fibrillation (AF), Atrial Enlargement, LVF, Conduction Defect, Conduction Abnormalities, Heart Block, Valvular Diseases, Cardiac Output, Low, Stroke Volume, Stroke Volume Variation, Hyperkalemia, Hypercalcemia, Hypocalcemia, LV Dysfunction, QT Prolongation, Sudden Cardiac Death Due to Cardiac Arrhythmia, Ventricular Arrhythmia, Pacing, Pacing Induced Dyssynchrony, Silent Ischemia, Pericarditis, Sleep Related Breathing Disorder, RSA, Apnea, Obstructive, Cardiac Output Measurement, Respiratory Impedance, CRT And/or ICD, Infarction, Cardiomyopathies, Primary, Hypertrophy
Interventions
SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C, SUBPROTOCOL D, SUBPROTOCOL E, SUBPROTOCOL F, SUBPROTOCOL G, SUBPROTOCOL H
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jun 11, 2026, 3:42 PM EDT
Terminated Not applicable Interventional

Ablation Versus Medical Management of Atrial Fibrillation in HFpEF

NCT04282850
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure With Normal Ejection Fraction
Interventions
Pulmonary Vein Isolation
Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Early Phase 1 Interventional

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction

NCT07634640
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Ferumoxytol infusion
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Not applicable Interventional

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

NCT04592445
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF
Interventions
Greater Splanchnic Nerve Ablation, Sham Control
Device
Lead sponsor
Axon Therapies, Inc.
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

NCT03843060
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
AZD9977, Itraconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

NCT04945460
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

NCT02885636
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Jun 11, 2026, 3:42 PM EDT
Recruiting Not applicable Interventional

BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching

NCT07413198
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
multi-domain behavioral, coaching, and exercise protocol
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 11, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade in HF With Preserved EF

NCT02173548
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jun 11, 2026, 3:42 PM EDT